معلومات عن هذا البودكاست 🔗

المضيفون:
تردد التحديث:
weekly
متوسط ​​طول الصوت:
29 minutes
مقابلات الضيوف
لديها رعاة
فرنسي
فرنسا
144 حلقة
منذ 15 مايو، 2023
episodic

أحدث حلقة 🔗

Comment faire accepter le changement sans que les équipes aient le sentiment que leur travail passé est remis en question ? Pour Loïc Lagarde, dirigeant de la Clinique Pasteur à Toulouse, changer ne signifie pas que ce qu’on faisait avant était mauvais. Cela signifie que nos pratiques doivent évol…

البحث في الحلقات الماضية

البحث في الحلقات السابقة من Pharma Minds.

الحلقات السابقة

What if Europe’s “innovation wave” isn’t quite what we think it is? In this bonus episode of Pharma minds’ Europe’s Access Dilemma, I speak with Dr. Sabine Vogler, health economist, Head of the Pharmacoeconomics Department at the Austrian National Public Health Institute (GÖG) and of the WHO Colla…
"The worst of all outcomes is the current default: the level of Europe's contribution to the world will be decided by America." – Graham Cookson, Economist Welcome to the 5th episode of Europe's Access Dilemma, the Pharma Minds mini-series on MFN and access to innovation in Europe. Pay more. Wait …
What happens to pharmaceutical innovation when your competitive window shrinks from eight years to just three? In this episode of Pharma minds, I speak with Marine Baxendell, CFO and co-fonder at xcube.bio, about a fundamental shift in the economics of pharma innovation. Science is moving faster.…
MFN isn't just a pricing debate. It is already changing how pharma companies think about where, when and how they launch new medicines. In this episode of Pharma minds, I speak with Laure Nas de Tourris, Partner at Clarivate, about what she is seeing on the ground as pharma and biotech leaders sta…
What if Europe’s answer to the rising cost of pharmaceutical innovation wasn’t simply to pay more, but to develop differently? In this episode of Pharma minds, I speak with Franck Le Deu, one of the few European voices with decades of first-hand experience inside Asia’s rapidly evolving biopharma …
What happens when making medicines cheaper in the US makes Europe less attractive for pharmaceutical innovation? In this episode of Pharma minds, I speak with Christoffer Frendesen, a Brussels-based pharmaceutical journalist specializing in pricing and market access, about one of the most conseque…
Compléments alimentaires, cosmétiques, huiles essentielles, biocides, laits infantiles... Certains produits se situent à la frontière de plusieurs catégories réglementaires. Et selon leur composition, leur destination ou leur présentation, leur statut peut changer. Dans cet épisode de Pharma Minds…
Organizations demand infinite growth in finite markets. Leaders are left at the crossroads of irreconcilable missions, balancing economic imperatives with the well-being of their teams. What happens when the equation simply has no solution? The cost of execution is sometimes your own breaking point…
You can have the best science in the world, but it means nothing if your company runs out of cash. When resources are limited and markets are unforgiving, execution ceases to be a management theory. It becomes a strict matter of survival. What does it actually cost to fund biotech innovation withou…
إخلاء المسؤولية: البودكاست والأعمال الفنية المضمنة في هذه الصفحة مأخوذة من Nathalie Lahitte، وهي مملوكة لمالكها وليست تابعة لشركة Listen Notes, Inc أو معتمدة منها.